The phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) (PAM) pathway is frequently activated in breast cancer, with PIK3CA being the most commonly mutated gene of significance in estrogen receptor (ER) positive breast cancer.1 This evidence concerns the gene AKT1 and breast cancer.